. 2008 Oct 17;58(4):475–492. doi: 10.1007/s00262-008-0598-y

Table 4.

Clinical trials of combined active specific IT and CT

graphic file with name 262_2008_598_Tab4_HTML.jpg

^aCT/IT/CT + IT

^bIT/IT + CT

Ab antibody, AML acute myelogenous leukemia, BCG Bacillus Calmette Guerin, BCNU 1, 3-bis-(2-chloroethyl)-1-nitrosourea, CPT-11 irinotecan, CR complete response, CT chemotherapy, CY cyclophosphamide, DC dendritic cells, DFS disease free survival, i.d. intradermally, IFA incomplete Freund’s adjuvant, IT immunotherapy, MR mixed response, MTX Methotrexate, MVA modified vaccinia Ankara, NR no response, NT not tested, OR objective (>50%) regression, PD progressive disease, p.o. per os, PMT progression median time, PR partial response, PSA prostate-specific antigen, rF recombinant fowlpox virus, rV recombinant vaccinia virus, s.c. subcutaneously, SD stable disease, TAP tumor associated peptides, TAX paclitaxel, TS-1 5-FU derivative, VP-16 etoposide